Open an Account
search icon
3
NOTIFICATIONS
Best Algo trading app in India
Bigul

BAFNA PHARMACEUTICALS LTD. - 532989 - Proposed Sale Of Equity Shares Of Bafna Pharmaceuticals Limited By SRJR Life Sciences LLP, Through Open Market Sale For Achieving Minimum Public Shareholding.

 In accordance with the requirements of Rule 19(2)(b) and 19A(5) of the Securities Contract (Regulation) Rule, 1957 and Regulation 38 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, read with Para 2(a) and Para (3) of the SEBI circular No. SEBl/HO/CFD/ CMD/CIR/P/43/2018 dated February 22, 2018 ("Circular") in connection with manner of achieving minimum public shareholding, we wish to inform the following details with respect to the intention of SRJR Life Sciences LLP ("Seller''''), member of our Promoter Group, for sale of equity shares ("Equity Shares") of Bafna Pharmaceuticals Limited (the "Company") held by it, as per the following details
08-03-2022

Bafna Pharma Standalone December 2021 Net Sales at Rs 20.46 crore, up 17.08% Y-o-Y

 NULL
11-02-2022
Bigul

BAFNA PHARMACEUTICALS LTD. - 532989 - Inadvertent Trade By Designated Person

 We reliably understand, Mr. Bafna Mahaveer Chand had purchased 3354 equity shares of Bafna Pharmaceuticals Limited on various dates from 30th July 2021 to 09th February 2022. The Audit Committee of the Company was notified of this incident and based on Mr. Bafna Mahaveer Chand ''s submission, it is felt that these were inadvertent trades made without any intent to violate the Bafna Pharmaceuticals Limited''s Code on Prohibition of Insider Trading (Bafna Pharmaceuticals Limited - Code) or the SEBI (Prohibition of Insider Trading) Regulations, 2015 (SEBI PIT Regulations) and SEBI (Substantial Acquisition of Shares and Takeovers) Regulations 2011 ('Takeover Regulation') by Mr. Bafna Mahaveer Chand. However, as there was an infraction of the Bafna''s Code and the SEBI Regulations by Mr. Bafna Mahaveer Chand, a penalty of Rs.1,50,000/ (Rupees One Lakh Fifty Thousand) has been imposed on him upon examination and confirmation by the Audit Committee at its meeting held on Feb 09, 2022
10-02-2022
Bigul

BAFNA PHARMACEUTICALS LTD. - 532989 - Result

 We would like to inform you that the Board at its meeting held on today approved: 1. The un-audited financial results for the Third Quarter ending 31st December 2021. Please find attached the un-audited financial results for Third Quarter ending 31st December 2021 along with the Limited Review Report obtained from the statutory auditor of the Company
10-02-2022
Bigul

BAFNA PHARMACEUTICALS LTD. - 532989 - Board Meeting Outcome for Outcome Of Board Meeting

 outcome of board meeting
10-02-2022
Bigul

BAFNA PHARMACEUTICALS LTD. - 532989 - Board Meeting Intimation for Q3 Results And Other Business

 BAFNA PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/02/2022 ,inter alia, to consider and approve Notice is hereby given that a meeting of the Board of Directors of the Company will be held on Thursday, 10th February 2022, to inter alia consider and adopt un-audited financial results for the quarter and nine months ended 31st December 2021 and any other business with the permission of the Chair.
01-02-2022
Bigul

BAFNA PHARMACEUTICALS LTD. - 532989 - Shareholding for the Period Ended December 31, 2021

 Bafna Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2021. For more details, kindly Click here
20-01-2022
Bigul

BAFNA PHARMACEUTICALS LTD. - 532989 - Closure of Trading Window

 As per SEBI (Prohibition of Insider Trading) Regulations, 2015, the 'Trading Restriction Period' shall be made applicable from the end of every quarter till 48 hours after declaration of financial results. In view of the aforesaid, it is hereby intimated that the trading window of the Company would be closed and shall be opened on 48 hours after declaration of Unaudited Financial Results of the Company for the quarter ended December 31, 2021. It is requested to the designated persons and their immediate relatives to ensure compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015 and shall not trade or deal otherwise in the Company's Securities during the trading window closure.
19-01-2022
Bigul

BAFNA PHARMACEUTICALS LTD. - 532989 - Statement Of Investor Complaints For The Quarter Ended December 2021

 No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- JITENDRA KUMAR PALDesignation :- Company Secretary and Compliance Officer
19-01-2022
Bigul

BAFNA PHARMACEUTICALS LTD. - 532989 - Revised Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.

 The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on January 13, 2022 for Mahveer Chand Bafna, Mahaveer Chand Bafna HUF, Sasikala Bafna, Amribai Bafna and Paras Bafna
13-01-2022
Next Page
Close

Let's Open Free Demat Account